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Abstract
Sphingosine-1-phosphate (S1P) lyase is a vitamin B6-dependent enzyme that
degrades sphingosine-1-phosphate in the final step of sphingolipid metabolism.
In 2017, a new inherited disorder was described caused by mutations in SGPL1,
which encodes sphingosine phosphate lyase (SPL). This condition is referred to
as SPL insufficiency syndrome (SPLIS) or alternatively as nephrotic syndrome
type 14 (NPHS14). Patients with SPLIS exhibit lymphopenia, nephrosis,
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PN, pyridoxine; S1P, sphingosine-1-phosphate; SCID, severe combined immunodeficiency; SPL, sphingosine phosphate lyase; SPLIS, sphingosine
phosphate lyase insufficiency syndrome; TREC, T-cell receptor excision circles.
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adrenal insufficiency, and/or neurological defects. No targeted therapy for
SPLIS has been reported. Vitamin B6 supplementation has therapeutic activity
in some genetic diseases involving B6-dependent enzymes, a finding ascribed
largely to the vitamin's chaperone function. We investigated whether B6 supple-
mentation might have activity in SPLIS patients. We retrospectively monitored
responses of disease biomarkers in patients supplemented with B6 and measured
SPL activity and sphingolipids in B6-treated patient-derived fibroblasts. In two
patients, disease biomarkers responded to B6 supplementation. S1P abundance
and activity levels increased and sphingolipids decreased in response to B6. One
responsive patient is homozygous for an SPL R222Q variant present in almost
30% of SPLIS patients. Molecular modeling suggests the variant distorts the
dimer interface which could be overcome by cofactor supplementation. We dem-
onstrate the first potential targeted therapy for SPLIS and suggest that 30% of
SPLIS patients might respond to cofactor supplementation.
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1 | INTRODUCTION
Sphingolipidoses are lysosomal storage disorders caused by
inactivating mutations in genes involved in the degradation
of complex sphingolipids.1 Sphingolipids are metabolized
through a common degradative pathway, which results in
the production of bioactive intermediates, such as ceramide,
sphingosine, and sphingosine-1-phosphate (S1P). These
intermediates play important roles in cell signaling,
programmed cell death, vascular biology, and immune cell
trafficking.2 Recently, inborn errors of metabolism affecting
enzymes involved in degradation of ceramides and sphingoid
bases have been discovered.3,4 These conditions represent
non-lysosomal, atypical sphingolipidoses that exhibit distinct
pathophysiology and require unique therapeutic strategies.5
Sphingosine phosphate lyase (SPL) is a pyridoxal-50-
phosphate (PLP)-dependent enzyme that catalyzes the
irreversible catabolism of S1P and other phosphorylated
sphingoid in bases in the final metabolic step of
sphingolipid degradation.6,7 In 2017, a novel syndrome
was described, caused by inactivating bi-allelic patho-
genic variants in SGPL1, which encodes SPL.8-12 This
condition, which is referred to as nephrotic syndrome
type 14 (NPHS14) or SPL insufficiency syndrome (SPLIS),
is associated with steroid-resistant nephrotic syndrome,
adrenal insufficiency, ichthyosis, lymphopenia, and neu-
rological defects.13 The number of reported cases is now
over 40.14-16 The age range and clinical presentations of
SPLIS are broad, and the natural history remains poorly
understood. Many SPLIS patients are diagnosed after
irreversible damage to kidneys, adrenal gland or nervous
system have already occurred. Clinical management has
largely focused on treating complications.
Some SGPL1 missense variants affect SPL residues not
directly involved in the enzyme's catalytic activity. As in
many other inborn errors of metabolism, there is evidence
that these non-catalytic site variants may lead to structural
variations that can induce SPL protein misfolding, aggre-
gation and/or proteasomal clearance.11 Reducing SPL mis-
folding with pharmacological chaperones could represent
a potential therapeutic approach for SPLIS.13 Interestingly,
the SPL cofactor PLP—the active form of vitamin B6—has
been shown to function as a chaperone in inborn errors of
metabolism involving PLP-dependent enzymes.17,18
We now provide biochemical and immunological evi-
dence that two SPLIS patients responded to B6 supplemen-
tation, supported by findings in patient-derived fibroblasts.
2 | METHODS
2.1 | Study participants
Following informed consent, we obtained clinical data,
blood samples, skin biopsies, or archived skin fibroblast
samples from individuals with SPLIS from worldwide
sources. Approval for human subject research was
obtained from the UCSF Benioff Children's Hospital Oak-
land Institutional Review Board, the National University
Health System, Washington University Medical Center,
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and from the local human subjects Review Boards
(Harran University Medical Center and King Saud Uni-
versity Medical Center). Control skin fibroblast lines used
in this study were generated as previously reported.11
All procedures followed were in accordance with the
ethical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2000 .
Informed consent was obtained from all patients for
being included in the study. Additional informed consent
was obtained from all patients for which identifying
information is included in this article.
2.2 | Genetic testing methods
For cases 1 to 6, whole-exome or -genome sequencing
was performed by next-generation sequencing on blood
samples using accredited commercial or academic labora-
tories (Cases 1 and 2, no parental testing done, Centogene,
Rostock, Germany; Case 3, trio Cincinnati Children's Hos-
pital Medical Center Division of Human Genetics Diag-
nostic Laboratory; Case 4, trio, Centogene; Case 5, trio
Rady Children's Institute for Genomic Medicine, San
Diego, California; Case 6 Centogene, parental alleles con-
firmed by Sanger sequencing). In each case, SGPL1 was
the only gene in which pathogenic variants were reported.
In case 7, diagnosis was made with a nephrotic syndrome
gene panel showing positivity for SGPL1mutations in both
alleles (Prevention Genetics). The diagnosis of SPLIS was
assigned when patients presented with one or more of the
main disease features (neurological/developmental defect,
nephrotic syndrome, primary adrenal insufficiency,
lymphopenia, acanthosis/ichthyosis) and genetic testing
identified SGPL1 pathogenic variants. In some cases,
genetic testing of the parents was confirmatory, but this
was not carried out in all cases.
2.3 | Primary fibroblast lines
Archived primary fibroblast lines were provided when
available. In other cases, primary fibroblasts were isolated
from fresh skin punch biopsy using a previously reported
protocol with some modifications.19 Briefly, using a sterile
blade skin biopsy was cut into 10 to 15 evenly sized pieces,
which were placed in 1% collagen type I (Millipore Sigma,
3867-1VL)-coated six-well plates containing 800 μL
Dulbecco's Modified Eagle's Medium (DMEM) plus 20%
fetal bovine serum (FBS). Plates were incubated at 37C,
and 200 μL DMEM plus FBS was added every 2 days. Once
the fibroblasts reached confluence, the cells were sub-
cultured and maintained in DMEM plus 10% FBS.
2.4 | Generation of immortalized
fibroblasts
Primary fibroblasts were transduced with hTERT using
the lentivirus vector plv-hTERT-IRES-hygro (Addgene
plasmid # 85140). Two days after transduction, 100 μg/
mL hygromycin was added for selection. After stable cells
were selected, the immortalized fibroblast lines were
amplified and sub-cultured for further experiments.
2.5 | SPL activity assay
SPL activity was quantified in whole-cell extracts of pri-
mary skin fibroblasts from SPLIS patients and control
fibroblasts by measuring the formation of the (2E)-
hexadecenal product. This was performed by quantifica-
tion of a hydrazine derivative of the product by liquid
chromatography–tandem mass spectrometry (LC-MS/
MS) separation with multiple reaction monitoring essen-
tially as described.20 Briefly, 90% confluent fibroblasts
propagated in 100 mm tissue culture dishes were washed
twice with ice-cold PBS, scraped in 1 mL PBS, and cell
pellets were harvested after centrifugation for use in SPL
activity assays and lipidomic analysis. For SPL activity
assay, 40 μg fibroblast protein extract was incubated with
50 μM S1P substrate in the reaction buffer (50 mM potas-
sium phosphate buffer pH 7.4, 1 mM EDTA, 5 mM DTT,
0.4 mM pyridoxal 5'-phosphate,100 mM sucrose, 0.1%
Triton X -100) for 1 hour. The reaction was stopped and
product derivatized by addition of derivatization buffer
(5 mM 2-hydrazinoquinoline, 5% perchloric acid in aceto-
nitrile) for 1 hour. (2E)-hexadecenal(d5) (Avanti Polar
Lipids, Inc. # 857476) was added as internal standard,
and product was quantified by LC–MS/MS using an
Agilent 6490 triple quadrupole mass spectrometer
coupled with a 1290 high-performance liquid chromatog-
raphy instrument.
2.6 | Sphingolipid quantitation
Anticoagulated blood samples obtained over time from
patient 4 were placed on ice until plasma isolation by
centrifugation the same day, after which plasma was
maintained at −20C until use. Lipid extraction and S1P
quantitation were performed locally by LC-MS/MS after
derivatization with TMS-diazomethane as previously
described.21 For all other blood samples, plasma was iso-
lated by centrifugation locally, maintained at −20C, and
shipped overnight on dry ice to the corresponding
author's laboratory where lipid extraction and S1P quan-
titation by LC-MS/MS were performed as we described.22
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Sphingolipid quantitation of cell pellets was performed in
similar manner.
2.7 | Western blotting
Western blotting was performed on fibroblast whole-cell
extracts as we described.23 Human SPL was detected
using a polyclonal anti-human SPL (R&D Systems) at
1:2000. GAPDH loading control, was detected using anti-
GAPDH (Santa Cruz Biotechnology) at 1:10 000. Signals
were visualized using the SuperSignal West-Pico kit
(Fisher Scientific, Rockford, Illinois) and quantified by
densitometry using ImageJ software (NIH).
2.8 | Pyridoxal 50-phosphate and B6
vitamer treatment
SPLIS patient fibroblasts were grown in custom RPMI
medium lacking all B6 vitamers (GE Healthcare—
Hyclone) and 10% FBS for 1 week. B6 vitamers pyridoxal
(PL), pyridoxine (PN), pyridoxamine (PM) or pyridoxal
50-phosphate (PLP) were delivered to fibroblast cultures
at a dose of 50 μM unless otherwise stated in poly-
ethylenimine (1 mg/mL stock in water). Cells were incu-
bated for an additional 5 to 7 days. Cells were harvested,
and whole-cell extracts were prepared for western blot-
ting, SPL assay or sphingolipid profiling.
2.8.1 | Molecular modeling of SPL
proteins
Wild type and R222Q mutant SPL proteins were analyzed
using the PyMOL Molecular Graphics System, Version
2.1. (Schrodinger, LLC, 2015).24
2.8.2 | Statistical methods
Two-tailed Student's t test was used to establish signifi-
cant differences between treatment groups of N = 3 or
more, with P < .05 considered the cutoff for significance.
3 | RESULTS
3.1 | Identification of eight novel SGPL1
variants in seven patients with SPLIS
Seven unrelated cases from diverse geographic loca-
tions in the Middle East, Asia, and the United States
were diagnosed with SPLIS based on the identification
of bi-allelic pathogenic SGPL1 variants (Table S1). An
eighth case can be inferred from the history of a sib-
ling of patient 7 who died of a similar condition. Three
of the patients were homozygous for one pathogenic
variant, and four patients were compound heterozy-
gotes. Patients 1 and 4 harbored SGPL1 amino acid
substitutions that have been previously
reported.11,12,16 The remaining five patients harbored
novel SGPL1 pathogenic variants resulting in amino
acid substitutions (patients 2-7), truncation (patient
3), splicing defect (patient 5), and frameshift (patient
7) of the SPL open reading frame. Pathogenic variants
affecting the highly conserved PLP cofactor binding
domain (exons 10-12) appear most frequently. One novel
pathogenic variant resulted in a substitution at residue
353, replacing the cofactor binding lysine with an arginine,
a change that is known to destroy enzyme activity.25
SPLIS-associated pathogenic variants identified to date
including those in the present cohort are represented sche-
matically in Figure S1. All patients in the current cohort
presented with at least one feature of SPLIS within the first
5 years of life (Table S2). Similar to other reports, glomeru-
lar kidney disease, and/or proteinuria was a prominent
feature in six of the seven SPLIS patients in our cohort. In
one case, renal pathology was consistent with collapsing
variant focal segmental glomerulosclerosis, an entity that
is associated with rapid progression to end-stage renal dis-
ease (Figure S2 and Table S3).26 In a retrospective analysis,
we found that two additional patients with SPLIS
exhibited collapsing variant focal segmental
glomerulosclerosis (Figure S2 and Table S3). Retinopathy
and other novel phenotypes observed in our cohort that
have not previously been reported in SPLIS patients are
described in Supplementary Material and shown in
Figure S3. Three out of four SPLIS patients exhibited high
circulating levels of the SPL substrate S1P in comparison
to healthy age-matched controls (data not shown).
3.2 | SPLIS patients uniformly exhibit
T-cell lymphopenia
All patients in our cohort exhibited lymphopenia, con-
sistent with the known role of SPL in regulating S1P
chemotactic gradients needed for lymphocyte egress
(Table S4).27,28 For the four patients in which T, B, and
natural killer (NK) cell populations were tested
(patients 3-7), three had pan-lymphopenia (patients
3–5), while one had isolated T-cell deficiency. Antibody
responses to vaccination were tested in four patients
and found to be protective (patients 2-5), although two
of those had low total immunoglobulin G (IgG) levels.
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Newborn screening for severe combined immunodefi-
ciency (SCID) detects the presence of naïve T-cells in
the peripheral blood using a quantitative PCR assay to
detect T cell receptor excision circle (TRECs), DNA
excised during T-cell receptor recombination.29 Two of
the three patients born in the United States at the time
of SCID newborn screening had abnormal TRECs
detected (Table S4).
3.3 | SPL biomarkers respond to vitamin
B6 supplementation in some SPLIS
patients
Given that vitamin B6 is a known cofactor for SPL and
that other metabolic disorders with B6 dependent
enzyme deficiencies can be B6 responsive, several
patients were placed on B6 supplementation by the
FIGURE 1 Immunological and biochemical responses to vitamin B6 treatment in patients 1 and 4. Repeated blood counts in patient
1 show (A) the absolute lymphocyte count (ALC) and (B) percent lymphocytes increased in response to pyridoxine treatment. Blood counts
before treatment, N = 14. Blood counts after initiation of treatment, N = 17. *P-value for absolute lymphocyte count before and after
treatment = .0025; P-value for percent lymphocytes before and after treatment = .0013. Repeated blood counts in patient 4 show (C) the
absolute lymphocyte counts and (D) percent lymphocytes increased in response to PLP and pyridoxine treatments. Blood counts before
treatment, N = 4. Blood counts after initiation of treatment, N = 13. *P-value for absolute lymphocyte counts = 7.2 × 10−5; P-value for
percent lymphocytes = .0002. In patient 4, T-cell CD3, CD4, and CD8 subsets were evaluated over time. Absolute subsets (E) and percentage
of each subset (F) increased after B6 was initiated. The P-value for percent CD3, CD4, and CD8 before and after treatment = .011, .017, and
.007, respectively; P-value for absolute CD3, CD4, and CD8 levels before and after treatment = 1.5 × 10−4, 2 × 10−4, and 2 × 10−4,
respectively. (G) Concentrations of S1P and dihydro-S1P measured in plasma of five controls matched by age, gender, and ethnicity to
patient 4. Data for patient 4 represent four different time points collected before any treatment was started. For each group, mean and
interquartile values are represented. (H) Concentration of patient 4 plasma S1P (d18:1), measured by targeted mass spectrometry before
(blue) and after (black) starting treatment with pyridoxal 50-phosphate. Time is indicated in months after the first plasma sample was taken
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treating physician. All four of these patients were already
in kidney failure at the time of B6 treatment. There was
no uniformity in the method of administration, dosage or
form of B6 supplementation. We then retrospectively col-
lected lab values from before and after B6 was instituted
in these patients. Considering the variable clinical fea-
tures in our cohort as well as the unlikely event that end-
organ damage would be reversed by B6 therapy, we gath-
ered information on the absolute lymphocyte count and
percent lymphocytes before and after the intervention as
a biomarker of SPL activity and B6-responsiveness in the
cohort. In patient 1 (homozygous R222Q), oral pyridox-
ine was initiated at 5 mg/kg/day. As shown in Figure 1A
and Table S4, the patient's absolute lymphocyte counts
increased significantly in response to pyridoxine. Simi-
larly, the percentage of lymphocytes increased in
response to therapy with B6 (Figure 1B). Neither patient
2 (homozygous G360V) nor patient 3 (heterozygous for
F290L and Y331*) responded to vitamin B6 supplementa-
tion (Table S4), and both died within months of starting
supplementation (Figures S4,S5). In patient 4 (heterozy-
gous S202L and Y416C), oral PLP was initiated at 30 mg/
kg/day. At baseline, the patient was persistently
lymphopenic (Figure 1C,D) and exhibited low CD3, CD4,
and CD8 counts with a decreased CD4/CD8 ratio
(Figures 1E-F and Table S4). There was also low
-mitogen response to phytohemagglutinin and conca-
navalin A (data not shown). Serum immunoglobulin G
(IgG) levels ranged from 1.77 to 3.89 g/L, and monthly
intravenous immunoglobulin was instituted for a period
of 2 years. PLP therapy was initiated, following which
IgG increased to 7.5 g/L in 4 months at which time the
intravenous immunoglobulin was discontinued. Begin-
ning at 4 months after therapy, CD3, CD4, CD8, and
CD4/CD8 ratio improved (Figures 1E,F, and Table S4).
At that time, pyridoxine given at 8 mg/kg/day
substituted for PLP due to persistently elevated liver
enzymes. Lymphocyte counts remained in the normal
range, and the liver enzymes improved. Clinically,
there was marked improvement in the patient's hair
growth and resolution of bald patches (data not shown).
Prior to instituting therapy, sphingoid base phosphate
SPL substrates were measured by LC-MS/MS in patient
4 plasma on five occasions in comparison to healthy
age-matched controls. Baseline plasma levels of the
major SPL substrate S1P were higher than age-matched
controls, whereas dihydro-S1P levels were lower
(Figure 1G). Retrospective analysis revealed that the
high plasma S1P levels in patient 4 declined subsequent
to the initiation of vitamin B6 supplementation
(Figure 1H). Both patients 1 and 4 remain alive and are
awaiting kidney transplantation 2 years after starting
vitamin B6 supplementation.
3.4 | SPL insufficiency is confirmed
using patient-derived fibroblasts
To confirm the biochemical impact of SGPL1 variants
identified in our cohort, primary fibroblast cell lines were
established from skin biopsy samples of patients 1 to
4. Cell lines were immortalized by stable expression of
hTERT. A previously reported healthy control primary
fibroblast line was also immortalized with hTERT.11 Both
primary and transformed lines were used for analysis of
SPL expression and activity levels and yielded similar
results. As shown in Figure 2A and Figure S6, SPL pro-
tein levels in primary SPLIS fibroblasts were variable,
FIGURE 2 Sphingosine phosphate lyase (SPL) protein expression and enzyme activity in sphingosine phosphate lyase insufficiency
syndrome (SPLIS) fibroblasts. Fibroblasts from SPLIS patients 1 to 4 and a healthy control were grown to confluence in B6 replete medium
plus 10% FBS, harvested by cell scraping, pelleted, and whole-cell extracts were used for both immunoblotting and SPL activity assays.
(A) SPL protein expression in primary fibroblasts from patients 1 to 4; N = 3 per group. For patients 1 to 3 fibroblasts vs control, P < .05; For
patient 4 fibroblasts vs control, P < 0.01. Significance was calculated based on image quantification results shown in Figure S6. (B) SPL
activity in primary fibroblasts from patient 1 to 4. N = 4 per group. For each of the four patient-derived fibroblasts vs control, P < .0003.
These results are representative of three separate experiments, with similar results obtained using either primary or transformed fibroblasts
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with cells from patients 1 to 3 exhibiting slightly lower
SPL expression levels than control, whereas patient
4 fibroblasts showed a profound reduction in SPL expres-
sion. Despite variability in SPL protein levels, all primary
SPLIS fibroblast lines exhibited significantly lower SPL
enzyme activity than controls (data not shown). Simi-
larly, transformed SPLIS fibroblast lines exhibited SPL
activity levels less than 10% of control levels (Figure 2B).
When sphingolipid profiling was performed, significantly
higher S1P levels were observed in all SPLIS fibroblast
lines compared to controls (Figure 3A). Three out of the
four SPLIS fibroblast lines also exhibited higher sphingo-
sine levels and lower dihydro-S1P levels than controls
(Figure 3B,C). Only patient 4 fibroblasts exhibited higher
dihydrosphingosine levels compared to control fibroblasts
(Figure 3D).
3.5 | SPLIS patient-derived fibroblasts
demonstrate responsiveness to treatment
with exogenous vitamin B6
Absolute lymphocyte counts and plasma S1P serve as
useful biomarkers of tissue SPL activity. We investigated
the impact of exogenous B6 on SPL abundance, activity
and S1P levels in patient 4 fibroblasts, as these cells had
the lowest SPL abundance and corresponded to a patient
who exhibited a clinical response to B6. Patient 4 fibro-
blasts were propagated for 1 week in medium lacking all
B6 vitamers, followed by an additional week in
B6-deficient medium (control) or medium supplemented
with B6 vitamers at 50 μM concentration, a dose chosen
based on previous literature describing B6 chaperone
effects.30 Comparison of SPL expression in fibroblasts
receiving vehicle, PLP, pyridoxal (PL) or pyridoxamine
(PM) revealed an increase in SPL abundance after treat-
ment with PLP and PM, as shown by western blotting in
Figures 4A and S7. Sphingolipid profiling in fibroblasts
treated with different B6 vitamers showed that the S1P and
sphingosine levels were significantly reduced after treat-
ment with PLP, PL, PM or PN—with PN and PM showing
greatest effect (Figures 4B-C). In contrast, no significant
changes were observed in dihydrosphingosine or dihydro-
S1P levels regardless of treatment (data not shown). Patient
4 fibroblasts were then propagated for 1 week in medium
containing a range of PN concentrations. A dose response
to PN, as shown by a reduction in cellular S1P, was detect-
able starting at 0.3 μM, with greatest effect at 50 μM
(Figure 4D). SPL activity was augmented in patient 4 fibro-
blasts by treatment with 50 μM PN (Figure 4E).
FIGURE 3 Sphingolipid profiles in sphingosine phosphate lyase insufficiency syndrome (SPLIS) fibroblasts. Primary and transformed
skin fibroblasts from SPLIS patients 1 to 4 and a healthy control were grown to confluence in B6 replete medium plus 10% fetal bovine
serum (FBS), harvested by cell scraping, pelleted, and whole-cell extracts were used for analysis of sphingoid bases and sphingoid base
phosphates. Results are shown for primary fibroblasts: (A) Sphingosine-1-phosphate (S1P); (B) Dihydrosphingosine-1-phosphate (Dihydro-
S1P); (C) Sphingosine; (D) Dihydrosphingosine (DHS). Each sample was run in triplicate (N = 3); *For S1P levels: patient 1 vs control,
P = .03; patient 2 vs control, P < .0006; patient 3 vs control, P = .001; patient 4 vs control, P < 5.7 × 10−6. For DihydroS1P levels: patient 1 vs
control, P = .07; patient 2 vs control, P = .04; patient 3 vs control, P = .02; patient 4 vs control, P < .0003. For all other results, * P < .05.
These results are representative of three separate experiments, with similar results obtained using either primary or transformed fibroblasts
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3.6 | Response of SPLIS patient-derived
fibroblasts to PN treatment correlates with
in vivo response
Finally, all four SPLIS patient-derived fibroblast lines
were compared for their responsiveness to 50 μM PN
based on reduction in cellular sphingolipids. Fibroblasts
derived from patients 1 and 4 demonstrated PN respon-
siveness, as shown by the reduction in total cellular S1P
levels (Figure 5A) and sphingosine levels (Figure 5B). In
contrast, fibroblasts from patients 2 and 3 were unre-
sponsive to PN based on lack of significant changes in
cellular S1P and sphingosine (Figure 5A,B). No consis-
tent differences in cellular dihydrosphingosine or dihydro
S1P levels were observed between treated and untreated
fibroblasts from any of the four cases (Figure 5C,D).
3.7 | Molecular modeling of the B6
responsive R222Q variant of SPL
Using the crystal structure of human SPL with an inhibi-
tor molecule in the active site as a guide,31 we interro-
gated the predicted impact of the SPLR222Q substitution.
Within SPL AB dimers, the arginine 222 side chain of
monomer A donated by helix 210 to 227, stabilizes the C-
terminus of helix 243 to 252 of monomer B and main-
tains the register of the helices through direct interac-
tions with both helices in a symmetrical arrangement, as
shown in Figure 6A. Substituting glutamine for arginine
would abrogate charge-dipole interactions at the C-
terminus of helix 243 to 252, compromising helix stability
due to electrostatic repulsion, represented in Figure 6B.
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FIGURE 4 A sphingosine phosphate lyase insufficiency syndrome (SPLIS) patient-derived fibroblast line responds to exogenous PLP
and B6 vitamers. Patient 4 fibroblasts were maintained for 1 week in B6-deficient medium and 10% fetal bovine serum (FBS), then switched to
B6-deficient medium plus B6 vitamer. Cells were harvested by cell scraping, pelleted, and whole-cell extracts were used for immunoblotting,
sphingolipid quantitation or sphingosine phosphate lyase (SPL) assays. (A) SPL protein levels determined by immunoblotting. N = 3 per
condition. For pyridoxal (PL) vs vehicle, no significant difference was observed. For PLP vs vehicle control (Ctrl) and pyridoxamine (PM) vs
control, P < .05. Significance was calculated based on image quantification results shown in Figure S7. (B) Sphingosine-1-phosphate (S1P)
and (C) Sphingosine in cells treated with the indicated B6 vitamer; N = 4 per group. *For S1P: P < .0003 for all vitamers vs control. + For
sphingosine: P ≤ .01 for all vitamers vs control. These results are representative of three separate experiments. (D) Patient 4 transformed
fibroblasts were maintained for 1 week in B6-deficient medium and 10% FBS, then switched to B6-deficient medium-plus vehicle control (Ctrl)
or a range of PN doses from 0.3 to 50 μM. Cells were harvested by cell scraping, pelleted, and whole-cell extracts were used for S1P quantitation
after 1 week of incubation in the stated conditions. N = 3 per condition. *For 0.3, 1.0, and 10 μM vs vehicle, P < .005. + For 50 μM vs vehicle,
P < .002. (E) Patient 4 transformed fibroblasts were maintained for 1 week in B6-deficient medium and 10% FBS, then switched to B6-deficient
medium-plus vehicle control (Ctrl) or plus 50 μM PN. After 1 week of incubation in the stated conditions, whole-cell extracts were harvested
and SPL enzyme activity measured. N = 3 per condition; *P = .035 for PN vs control
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repositioning the N-terminus of helix 243 to 252, a key
determinant for PLP recognition. A reduction in binding
affinity for PLP could be compensated for by increasing the
concentration of PLP through vitamin B6 supplementation.
Using Boltzmann's equation,32 we calculated that increas-
ing the concentration of PLP by 100 to 200-fold (equivalent
to pharmacological PN dosing) should compensate for the
reduction in dimer stability and rescue the minor energetic
defects introduced via the glutamine substitution. Destabi-
lization of the intact, active, dimeric SPL structure due to
the glutamine substitution could be compensated for by
PLP binding through multiple direct hydrogen bonds with
residues of both monomers and a water molecule and
extensive van Der Waals interactions. PLP could addition-
ally act as a chaperone if covalently bound to SPL, regard-
less of the Km for PLP in solution.
4 | DISCUSSION
In this report, we describe seven new SPLIS cases with
one additional presumed case. Thus, we contribute 18%
of the world's diagnosed cases of SPLIS, bringing the total
known patients close to 50. SPL insufficiency causes
accumulation of the enzyme's main substrate S1P, consis-
tent with our finding of high S1P levels in patient plasma
and skin fibroblast lines. The low plasma dihydro-S1P
levels observed in patient 4 could be explained by the fact
that dihydro-S1P is generated via the de novo pathway,
which may be inhibited by ORM proteins in the presence
of high sphingolipid concentrations.33 This differential
effect also suggests that the plasma S1P/dihydroS1P ratio
could be helpful in confirming the diagnosis in patients
with typical disease features and missense SGPL1 vari-
ants of unknown significance. We observed several
unusual features, including two cases of retinopathy and
three cases of collapsing variant focal segmental
glomerulosclerosis (one in our series and two in previ-
ously reported cases). Further analysis will be required to
establish the frequency of these conditions in the context
of SPLIS. The wide range in severity and heterogeneity of
SPLIS presentations could be explained by the degree of
SPL inactivation. However, long-term follow up will be
required to characterize the natural history of SPLIS and
confirm genotype to phenotype correlations.
All patients in our cohort exhibited lymphopenia,
which highlights the importance of the known role of SPL
in generating S1P gradients that control lymphocyte migra-
tion.27,28 Two patients exhibited pan lymphopenia and two
exhibited T-cell-specific lymphopenia. S1P receptors are
present on all major lymphocyte populations, and S1P gra-
dients are thought to be important signals for lymphocyte
migration.27,28 It is uncertain why there is variability in B-
and NK-cell lymphopenia, but it could be related to the
FIGURE 5 Response of sphingosine phosphate lyase insufficiency syndrome (SPLIS) patient fibroblasts to PN treatment correlates with
in vivo response. Fibroblasts from patients 1 to 4 were maintained for 1 week in B6-deficient medium and 10% FBS, then switched to
B6-deficient medium plus 50 μM PN. After 1 week of incubation in the stated conditions, whole-cell extracts were harvested and
sphingolipid quantitation performed. (A) S1P; (B) Sphingosine; (C) dihydroS1P (DHS1P); (D) dihydrosphingosine (DHS). N = 3 per group;
*P < .05 or greater significance. For patient 1, PN vs vehicle: S1P, P < .0004 and Sphingosine, P = .03. For patient 2, PN vs vehicle and
patient 3, PN vs vehicle, no significant differences in S1P or sphingosine were observed. For patient 4, PN vs vehicle: S1P, P < .002 and
sphingosine, P < .0007. These results are representative of three separate experiments
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presence of other receptors that promote migration of these
lymphocytes. The positive response of SPLIS patients to
vaccine challenge suggests that while circulating lympho-
cytes are low, functional responses may be intact. However,
some patients with SPLIS develop recurrent infections,
suggesting that SPLIS could be considered a monogenic
cause of immune deficiency.
The greatest significance of our study lies in the
responsiveness of two SPLIS patients to cofactor supple-
mentation as measured by its impact on two biomarkers
of SPL activity, namely plasma S1P levels and lympho-
cyte counts. The rise in lymphocyte counts in response to
B6 was mirrored by increased SPL protein and activity
and reduced sphingolipids in patient-derived fibroblasts.
PLP serves as a cofactor for more than 140 different
enzyme reactions.34 In addition to its catalytic functions,
PLP can serve as a chaperone, facilitating the folding of
nascent polypeptides of some PLP-dependent enzymes to
attain their optimally active three-dimensional struc-
tures.17 This feature of PLP has been leveraged therapeu-
tically in primary hyperoxaluria and other metabolic
diseases.35,36
No targeted therapy is currently available for patients
with SPLIS. Our results suggest that some manifestations of
SPLIS may be preventable by cofactor supplementation in
patients with B6-responsive SGPL1 alleles. We speculate
that other chaperone-type drugs could also potentially be
useful in the treatment of SPLIS. Studies comparing murine
“SPL knockout” mice which die at weaning to “humanized
SPL knock-in” mice which have 10% to 20% of normal SPL
activity and are healthy demonstrate that a small amount of
SPL activity may suffice to prevent serious sequelae of SPL
insufficiency.37 Thus, modest increases in SPL activity
afforded by B6 supplementation may be clinically conse-
quential. Lymphocyte trafficking is highly sensitive to dis-
turbances of S1P gradients, as shown by the persistent
lymphopenia in otherwise healthy humanized SPL knock-
in mice. Thus, the rise in lymphocyte counts we observed
may be a harbinger of a more global responsiveness of
SPLIS pathology to cofactor supplementation. Our results
demonstrating correlation between in vivo and in vitro
responsiveness to B6 suggest that skin fibroblasts may be
useful for theratyping, that is, establishing genotype-specific
responsiveness to B6 and/or other therapies.
FIGURE 6 Potential mechanism
of B6 interaction with SPL R222Q
mutant protein. (A) PyMol-generated
illustration of pyridoxal 50-phosphate
(PLP; black arrows) bound to wild type
sphingosine phosphate lyase (SPL)
monomers at the dimer interface.
Monomers within the dimer are
designated by green or yellow carbon
atoms, while the PLP moiety contains
cyan carbon atoms. Helix 243-252
(which would be distorted by
substitution of glutamine for arginine)
is shown in orange. R222 side chains
are shown in deep blue. (B)
Electrostatic PyMol surface
representations for wild type and
R222Q SPL homodimers illustrating
electrostatic repulsion (red) at the
dimer interface of the R222Q mutant
enzyme. The white box represents the
dimer interface and the arrows point to
the locations of R222 substituted by
Q222 in each mutant monomer
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Limitations of our study include the retrospective
design, lack of uniformity in the treatment regimen and
timing of intervention, lack of information on baseline
vitamin B6 status, and differences in patient genotypes,
age, medications, and medical history. Like many other
micronutrients, B6 contributes to optimal immune func-
tion with particular impact on lymphocytes, and supple-
mentation can alleviate neutropenia and lymphopenia
especially in individuals with B6 deficiency.38 In our
study, we used the lymphocyte count as a biomarker of
SPL function rather than as an indicator of overall
immune status, infection risk or chance of survival.
Although the two B6 responsive patients survived and
the two B6 non-responsive patients did not, the differ-
ences in outcome could have been due to many factors
that differed between patients including concurrent infec-
tions in patients 2 and 3, medications (particularly anti-
convulsants which may affect B6 bioavailability) and
SGPL1 pathogenic variant. Testing a standardized vita-
min B6 regimen for efficacy in well-designed prospective
longitudinal studies—ideally coupled with cell-based
testing—will be required before firm conclusions can be
drawn regarding the benefit of vitamin B6 in the context
of SPLIS.
The two B6-responsive SPLIS patients harbor previ-
ously reported SGPL1 pathogenic variants. Patient 1 is
homozygous for R222Q. Substitution of glutamine for
arginine disrupts the alignment of helices, distorting the
active site and reducing cofactor binding affinity. Impor-
tantly, the R222 residue is substituted in nearly 30% of
reported SPLIS cases. Thus, a significant proportion of
SPLIS patients might benefit from cofactor supplementa-
tion. Patient 4 is compound heterozygous for S202L and
Y416C. It is not possible to distinguish which allele is
responsive to B6 without further analysis. in vitro studies
measuring wild type and mutant SPL interactions and
mutant SPL protein folding in the presence of PLP will
be important next steps.
The greatest potential of cofactor supplementation
would be to prevent the devastating neurological sequelae
and end-organ damage to kidneys and endocrine glands
associated with SPLIS. The development of methods for
early diagnosis could provide a window of opportunity for
intervention with vitamin B6 supplementation or other
targeted therapies as they become available.
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